SPY335.84-2.98 -0.88%
DIA279.57-1.46 -0.52%
IXIC10,910.28-140.19 -1.27%

Exelixis Reports Collaboration For 3 Phase 3 Combo Trials For Patients With Advanced Solid Tumors

Benzinga · 12/19/2019 12:07